GODREJ CONSUMER PRODUCTS LTD. Q1 FY27 Results

Godrej Consumer Products posted consolidated revenue of ₹4,225.47 Cr for Q1 FY27 (quarter ended June 30, 2026), up 18.3% YoY on a like-for-like restated basis (+8.3% QoQ), with PAT of ₹504.52 Cr, up 11.5% YoY (+11.7% QoQ) and basic EPS of ₹4.93 versus ₹4.42 a year ago. This lands roughly in line with both management's own high-teens revenue guidance for the quarter (flagged July 3) and the Street's pre-result consensus of ~17% YoY consolidated revenue growth — not a beat, but on-plan. PAT growth trailing revenue growth reflects the margin compression management explicitly guided for on May 6: consolidated NPM eased to 12.0% from 12.7% a year ago, and OPM to 19.0% from 19.4%, consistent with the flagged 7-9% cost inflation being only partly offset so far by the 4-7% price hikes taken across categories.

The growth was unevenly sourced. Africa (including Strength of Nature) was the standout, with segment revenue up 47.1% YoY to ₹1,006.13 Cr and segment profit up 40.1% to ₹102.69 Cr — well ahead of management's guided "sustained double-digit growth" for the region. Indonesia grew a healthy 15.3% YoY to ₹486.91 Cr (profit +10.6%). India, the largest segment at roughly 60% of consolidated revenue, grew a comparatively modest 11.4% YoY to ₹2,557.41 Cr, with segment margin compressing to 20.7% from 23.2% a year ago — the clearest evidence of where the cost-inflation squeeze is biting hardest. This domestic softness shows up starkly in the standalone (largely India) numbers: standalone PAT grew just 2.3% YoY to ₹362.72 Cr on 11.4% revenue growth, with NPM down more sharply to 14.3% from 15.6%. Readers tracking the standalone print separately should note it is a materially weaker read than the consolidated headline — international operations, not the India "mothership," are doing the heavy lifting on profit growth this quarter.

The stock went into the print at ₹1,048, down 3.6% over the past month of trading.

For context: this is the highest quarterly PAT in the last 6 quarters on our records; revenue is at a 6-quarter high.

Exception items were a modest drag in both periods and roughly comparable in size, so they don't change the underlying picture much: consolidated exceptional charges of ₹15.56 Cr this quarter (Strength of Nature US litigation costs ₹7.96 Cr, India/Indonesia/Africa restructuring ₹9.10 Cr, partly offset by a ₹5.57 Cr labour-code gratuity/leave credit and a ₹4.07 Cr Muuchstac fair-value charge) compare with a ₹19.54 Cr charge a year ago; stripping both out, PBT before exceptionals grew 9.3% YoY (₹692.11 Cr vs ₹633.24 Cr), and adjusted PAT growth works out to roughly 10.5% — close to the 11.5% reported figure, confirming the one-offs aren't distorting the story either way. The Board also declared an interim dividend of ₹5/share (record date August 13, 2026), matching the dividend signal flagged ahead of this print. No separate management press release was available alongside this filing — only the board-outcome letter and financial statements.

GODREJCP expects high-teens consolidated revenue growth in Q1 FY27 (quarter ends Jun 30, results Aug 7), exceeding its full-year FY27 guidance of double-digit growth. This comes on the back of Q4 FY26's 11% sales growth, marking an acceleration despite persistent commodity cost pressures. The Street is decisively bullish—28 of 34 analysts rate BUY, with consensus 12-month targets of ₹1,250–₹1,450 (17–35% upside from ₹1,070). But the market's premium valuation (P/E 55.88x vs peer average ~45x) hinges on the company's ability to hold margins while chasing volume. That trade-off is the headline to watch.

A strong print would show high-teens revenue growth with volume growth tracking high single-digit and early signs of margin stabilization (e.g., sequential margin recovery, or cost initiatives offsetting commodity inflation). International segments (Indonesia, GAUM) showing continued momentum and market-share gains would support the Street's 17–35% upside case. A weak print would reveal margin compression deeper than 80 bps, volume growth faltering below high single-digit, or management guiding full-year FY27 growth below double-digits—any of which would test the premium valuation.

Yes, on trajectory. Q4 FY26 delivered 11% sales growth and 10% net profit growth, with underlying volume of 6%—a solid foundation. Q1 FY27 guidance of high-teens revenue growth is ahead of the full-year FY27 double-digit guide, signaling an early-fiscal acceleration. Management flagged Q1 benefiting from strong domestic demand, Indonesia's recovery (easing competitive intensity, profitability improving), and GAUM's expansion into new FMCG categories (haircare, oral care) with currency tailwinds. Cost pressures (raw materials, freights) have persisted since Q4, but the company has deployed price hikes and cost controls; the real proof is on Aug 7. FY27 full-year guidance remains double-digit growth—achievable if Q1 is high-teens, but dependent on margin recovery and sustained volume.

No material adverse events. The ₹200 Cr Pet Care investment (Jul 22) is strategic, signaling management's bet on high-growth pet-nutrition and pet-care verticals—a positive signal for long-term portfolio diversification. Insider window closure (Jul 1) is routine. Dividend payout and ESOP grants routine. No pledges or block deals flagged. Promoter holding stable at 53.05% (Q4). FII ownership declined 1.47 pp QoQ to 13.94% (Q4), while DII rose 1.52 pp to 18%. FII selling over the past two quarters (from 20.68% in Q3 FY25) worth monitoring—may reflect profit-taking after the stock's run-up to ATH ₹1,273.9 in recent months.

GCPL showed genuine Africa/Indonesia momentum and structural HI recovery, but faced steeper-than-guided margin pressure in India (LPG/kerosene trebled). Q1 revenue growth 15.4% vs. management's 19% claim. Margin guidance walked back (24-26% → 22-26%) signaling near-term headwinds. Long-term strategy intact; near-term caution warranted.

Analysts pressed hard on margin bridge (6% inflation vs 5% pricing), speedboat pace (3% vs. plan), Africa sustainability (25% too aggressive?), HI market share (one-quarter fluke?), and India volume recovery path. Management held ground — detailed commodity breakdown (LPG/kerosene/LABSA), explained timing lag (consumption vs. replacement), conceded near-term weakness but reaffirmed H2 recovery pattern. Some deflection on competitive details (Rizz pricing, Spic share) citing sensitivity. No material dodges; appropriate caution communicated.

Score 7/10. Clear on commodity cost breakdown and recovery mechanics. Defensive but honest when pressed on margin/pricing tradeoffs. Limited disclosure on competitive details (Rizz pricing, Spic market share) citing sensitivity — reasonable but leaves gaps in evaluation. Delivered on Africa turnaround (+25% CC) and Indonesia recovery (+10%). Speedboat pace behind plan (+3% vs. 100-150 bps target); new category execution (Rizz, pet care) still early-stage. H.I. market share gain structural but occurred in weak quarter. H2 FY26 margin recovery credible precedent.